Frühdiagnose der systemischen Sklerose

Zusammenfassung

Die frühe Diagnose der systemischen Sklerose (Sklerodermie) konnte in den vergangenen Jahren deutlich verbessert werden. Während früher die Erkrankung vorwiegend in fortgeschrittenen Stadien mit Schäden an Haut und inneren Organen erkannt wurde, ist es heute möglich, die Diagnose bei Patienten mit Raynaud-Phänomen zu stellen, wenn Sklerodermie-assoziierte antinukleäre Antikörper und/ oder Sklerodermie-typische kapillarmikroskopische Veränderungen nachgewiesen werden können. Die EULAR/ACR-Klassifikationskriterien von 2013 sind hier ein wichtiger Fort-schritt. Die frühe Diagnose ermöglicht den frühzeitigen Einsatz der heutigen Therapiemöglichkeiten und kann Schäden verhindern. Sie erlaubt darüber hinaus ein besseres Monitoring des Krankheitsverlaufs auf der Grundlage der Organdiagnostik und der nachgewiesenen Autoantikörper.

Summary

Early diagnosis of systemic sclerosis (scleroderma) has been improved during the last years. Whereas formerly the disorder was recognized not before progressive damage at the skin or internal organs has developed, today it is possible to confirm diagnosis in patients with Raynaud`s phenomenon, if scleroderma-associated autoantibodies and/ or typical changes in nailfold capillary microscopy are present. The EULAR/ACR classification criteria include these features and are an important progress allowing early treatment. Based on an early diagnosis and evaluation of organ involvement and with knowledge of the specificity of scleroderma associated autoantibodies a better disease monitoring is possible.

Schlüsselwörter

Systemische Sklerose - Sklerodermie - Früh-diagnose

Keywords

Systemic sclerosis - scleroderma - early diagnosis

• Literatur

• 1 Alarcon-Segovia D., Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989; 16: 328-334.
• 2 Arbuckle MR, McClain MT, Rubertone MV. et al Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
• 3 Czirjak L, Matucci-Cerinic M. Beyond Raynaud’s phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory. Rheumatology (Oxford) 2011; 50: 250-251.
• 4 Di CE, Battisti S, Di SA. et al Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). Eur J Radiol 2013; 82: e268-e273.
• 5 Frerix M, Meier FM, Hermann W, Muller-Ladner U. [Therapeutic management in early disease stages of systemic sclerosis: early diagnosis - early symptoms - early problems]. Z Rheumatol 2013; 72: 960-969.
• 6 Genth E, Mierau R. Autoantibodies in systemic sclerosis. Dtsch Med Wochenschr 2012; 137: 1758-1760.
• 7 Hunzelmann N. et al The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-1192.
• 8 Hunzelmann N, Genth E, Krieg T. et al Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS). Z Rheumatol 2008; 67: 334-340.
• 9 Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634-641.
• 10 Koenig M, Joyal F, Fritzler MJ. et al Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-3912.
• 11 LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.
• 12 Maricq HR, Weinberger AB, LeRoy EC. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 1982; 9: 289-291.
• 13 Masi AT, Rodnan GP, Medsger T. et al Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
• 14 Mierau R. et al Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011; 13: R172
• 15 Minier T, Guiducci S, Bellando-Randone S. et al Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014; 73: 2087-2093.
• 16 Moinzadeh P. et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2014 Jan 3. [Epub ahead of print]
• 17 Nielen MM, van Schaardenburg D, Reesink HW. et al Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-386.
• 18 Valentini G, Cuomo G, Abignano G. et al Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011; 50: 317-323.
• 19 Valentini G, Marcoccia A, Cuomo G. et al The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis. Curr Rheumatol Rev 2014; 10: 38-44.
• 20 Valentini G, Marcoccia A, Cuomo G. et al Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) 2014; 66: 1520-1527.
• 21 Van den Hoogen F. et al 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747.
• 22 Weiner ES, Hildebrandt S, Senecal JL. et al Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. A prospective study. Arthritis Rheum 1991; 34: 68-77.